|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genes expressed at higher levels in tFL than EBV(-)BL and EBV(+)BL included calcium/calmodulin-dependent protein kinase I (CAMK1) and mitogen-activated protein kinase 10 (MAPK10).
|
12967475 |
2003 |
|
Lennox-Gastaut syndrome
|
0.500 |
GeneticVariation
|
disease |
ORPHANET |
Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy.
|
16249883 |
2006 |
|
Epileptic encephalopathy
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy.
|
16249883 |
2006 |
|
Brain Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
These interactions are likely affected by a truncated JNK3 protein, and thereby provide an explanation for the link between alterations in MAP kinase signal transduction and brain disorders.
|
16249883 |
2006 |
|
Huntington Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additional experiments indicated that the effects of polyQ-Htt on FAT were mediated by neuron-specific JNK3 and not by ubiquitously expressed JNK1, providing a molecular basis for neuron-specific pathology in Huntington's disease.
|
19525941 |
2009 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
|
20525557 |
2010 |
|
Respiratory Function Tests
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction.
|
22837378 |
2012 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
This reveals AD as a metabolic disease that is under tight control by JNK3.
|
22958823 |
2012 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
This reveals AD as a metabolic disease that is under tight control by JNK3.
|
22958823 |
2012 |
|
Lennox-Gastaut syndrome
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
Epileptic encephalopathy
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
Langer-Giedion Syndrome
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
Intellectual Disability
|
0.110 |
AlteredExpression
|
group |
BEFREE |
We previously described a patient with intellectual disability (ID) and seizures (Patient 1), carrying a de novo chromosome translocation affecting the CNS-expressed MAPK10/JNK3 gene.
|
23329067 |
2013 |
|
Seizures
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
We previously described a patient with intellectual disability (ID) and seizures (Patient 1), carrying a de novo chromosome translocation affecting the CNS-expressed MAPK10/JNK3 gene.
|
23329067 |
2013 |
|
Cognition Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, strong repression of the c-Jun N-terminal kinase 3 (JNK3) mRNA expression was found in carcinoma cells which correlated with enhanced toxicity of PTX suggesting an essential role of the mitogen activated protein kinase (MAPK)/JNK signalling cascades pathway in the mechanisms of HNSCC cell resistance to PTX.
|
23409748 |
2013 |
|
Hyperactive behavior
|
0.110 |
GeneticVariation
|
phenotype |
BEFREE |
Over-expression of this hyperactive mutant in transgenic parasites led to a dominant negative effect causing massive cell death during amastigote differentiation, demonstrating the essential nature of MPK10 auto-inhibition for parasite viability.
|
25232945 |
2014 |
|
Ovarian Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Multivariate Cox regression analysis showed that elevated MAPK10 or ATG9A protein and lowered miR-29b mRNA expression in ovarian carcinoma was an independent poor prognostic predictor.
|
24767251 |
2014 |
|
Ovarian epithelial cancer stage II
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The percentage of positive myeloid cell leukemia sequence 1, ATG9A, and MAPK10 protein expression and low miR-29b mRNA expression were significantly higher in cases with clinical stage III and IV ovarian cancer than in cases with clinical stage II ovarian cancer.
|
24767251 |
2014 |
|
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Multivariate Cox regression analysis showed that elevated MAPK10 or ATG9A protein and lowered miR-29b mRNA expression in ovarian carcinoma was an independent poor prognostic predictor.
|
24767251 |
2014 |
|
Stage II Ovarian Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The percentage of positive myeloid cell leukemia sequence 1, ATG9A, and MAPK10 protein expression and low miR-29b mRNA expression were significantly higher in cases with clinical stage III and IV ovarian cancer than in cases with clinical stage II ovarian cancer.
|
24767251 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Multivariate Cox regression analysis showed that elevated MAPK10 or ATG9A protein and lowered miR-29b mRNA expression in ovarian carcinoma was an independent poor prognostic predictor.
|
24767251 |
2014 |
|
Neurodegenerative Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
JNK3 is predominantly found in the CNS neurons, making it an attractive target for neurodegenerative disorders.
|
26505831 |
2015 |
|
Microphthalmos
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the absence of JNK3, hyaloid vessel physiological pruning is impaired, associated with abnormal persistence of hyaloid vessels, defective retinal vasculature and microphthalmia.
|
25807892 |
2015 |
|
Spinal Muscular Atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
JNK3 deficiency prevents the loss of spinal cord motor neurons, reduces muscle degeneration, improves muscle fiber thickness and muscle growth, improves motor function and overall growth and increases lifespan of mice with SMA that shows a systemic rescue of phenotype by a SMN-independent mechanism.
|
26423457 |
2015 |